These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 21756025)
21. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens. Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201 [TBL] [Abstract][Full Text] [Related]
22. Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2,6 sialic acid-dependent and -independent interactions. Alborzian Deh Sheikh A; Akatsu C; Imamura A; Abdu-Allah HHM; Takematsu H; Ando H; Ishida H; Tsubata T Biochem Biophys Res Commun; 2018 Jan; 495(1):854-859. PubMed ID: 29146181 [TBL] [Abstract][Full Text] [Related]
23. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Loomis K; Smith B; Feng Y; Garg H; Yavlovich A; Campbell-Massa R; Dimitrov DS; Blumenthal R; Xiao X; Puri A Exp Mol Pathol; 2010 Apr; 88(2):238-49. PubMed ID: 20122924 [TBL] [Abstract][Full Text] [Related]
24. Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas. Rillahan CD; Macauley MS; Schwartz E; He Y; McBride R; Arlian BM; Rangarajan J; Fokin VV; Paulson JC Chem Sci; 2014 Jun; 5(6):2398-2406. PubMed ID: 24921038 [TBL] [Abstract][Full Text] [Related]
25. Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells. Enterina JR; Jung J; Macauley MS Biomed J; 2019 Aug; 42(4):218-232. PubMed ID: 31627864 [TBL] [Abstract][Full Text] [Related]
26. Sialic Acid Ligand Binding of CD22 and Siglec-G Determines Distinct B Cell Functions but Is Dispensable for B Cell Tolerance Induction. Özgör L; Meyer SJ; Korn M; Terörde K; Nitschke L J Immunol; 2018 Oct; 201(7):2107-2116. PubMed ID: 30143587 [TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of fully human anti-CD22 monoclonal antibodies. Xiao X; Ho M; Zhu Z; Pastan I; Dimitrov DS MAbs; 2009; 1(3):297-303. PubMed ID: 20065646 [TBL] [Abstract][Full Text] [Related]
28. Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22. Pfrengle F; Macauley MS; Kawasaki N; Paulson JC J Immunol; 2013 Aug; 191(4):1724-31. PubMed ID: 23836061 [TBL] [Abstract][Full Text] [Related]
30. Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas. Boons GJ Expert Rev Vaccines; 2010 Nov; 9(11):1251-6. PubMed ID: 21087105 [TBL] [Abstract][Full Text] [Related]
31. Characterisation of the Dynamic Interactions between Complex N-Glycans and Human CD22. Di Carluccio C; Crisman E; Manabe Y; Forgione RE; Lacetera A; Amato J; Pagano B; Randazzo A; Zampella A; Lanzetta R; Fukase K; Molinaro A; Crocker PR; Martín-Santamaría S; Marchetti R; Silipo A Chembiochem; 2020 Jan; 21(1-2):129-140. PubMed ID: 31095840 [TBL] [Abstract][Full Text] [Related]
32. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Tateno H; Li H; Schur MJ; Bovin N; Crocker PR; Wakarchuk WW; Paulson JC Mol Cell Biol; 2007 Aug; 27(16):5699-710. PubMed ID: 17562860 [TBL] [Abstract][Full Text] [Related]
33. Supramolecular complexing of membane Siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM. Cui L; Kitov PI; Completo GC; Paulson JC; Bundle DR Bioconjug Chem; 2011 Apr; 22(4):546-50. PubMed ID: 21405019 [TBL] [Abstract][Full Text] [Related]
34. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. Haas KM; Sen S; Sanford IG; Miller AS; Poe JC; Tedder TF J Immunol; 2006 Sep; 177(5):3063-73. PubMed ID: 16920943 [TBL] [Abstract][Full Text] [Related]
35. Identification of Siglec Ligands Using a Proximity Labeling Method. Chang L; Chen YJ; Fan CY; Tang CJ; Chen YH; Low PY; Ventura A; Lin CC; Chen YJ; Angata T J Proteome Res; 2017 Oct; 16(10):3929-3941. PubMed ID: 28899088 [TBL] [Abstract][Full Text] [Related]
36. Improved synthesis of CD22-binding sialosides and its application for further development of potent CD22 inhibitors. Suganuma Y; Imamura A; Ando H; Kiso M; Takematsu H; Tsubata T; Ishida H Glycoconj J; 2023 Apr; 40(2):225-246. PubMed ID: 36708410 [TBL] [Abstract][Full Text] [Related]
37. CD22 as a target for cancer therapy. Tu X; LaVallee T; Lechleider R J Exp Ther Oncol; 2011; 9(3):241-8. PubMed ID: 22070056 [TBL] [Abstract][Full Text] [Related]
38. Conformationally Constrained Sialyl Analogues as New Potential Binders of h-CD22. Forgione RE; Nieto FF; Di Carluccio C; Milanesi F; Fruscella M; Papi F; Nativi C; Molinaro A; Palladino P; Scarano S; Minunni M; Montefiori M; Civera M; Sattin S; Francesconi O; Marchetti R; Silipo A Chembiochem; 2022 May; 23(10):e202200076. PubMed ID: 35313057 [TBL] [Abstract][Full Text] [Related]
39. C-4 modified sialosides enhance binding to Siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy. Kelm S; Madge P; Islam T; Bennett R; Koliwer-Brandl H; Waespy M; von Itzstein M; Haselhorst T Angew Chem Int Ed Engl; 2013 Mar; 52(13):3616-20. PubMed ID: 23440868 [No Abstract] [Full Text] [Related]
40. N-Linked Glycosylation Regulates CD22 Organization and Function. Wasim L; Buhari FHM; Yoganathan M; Sicard T; Ereño-Orbea J; Julien JP; Treanor B Front Immunol; 2019; 10():699. PubMed ID: 31019513 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]